{"analyses":[{"ciLowerLimit":"0.371","ciPctValue":"95","ciUpperLimit":"0.638","groupDescription":"P-value was obtained from 1-sided log-rank test stratified by Eastern Cooperative Oncology Group performance status (ECOG PS) score, brain metastases, and prior epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) treatment. The hazard ratio and corresponding 95% confidence interval (CI) from the stratified Cox Proportional Hazards model were also presented.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"To control family-wise Type 1 error, a step-down procedure was applied in following order: PFS, objective response rate (ORR), overall survival (OS), and disease control rate (DCR). Statistical significance: 1-sided at alpha=0.025.","paramType":"Hazard Ratio (HR)","paramValue":"0.487","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.0","upperLimit":"8.8","value":"7.7"},{"groupId":"OG001","lowerLimit":"2.6","upperLimit":"4.3","value":"3.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"174"}],"units":"Participants"}],"description":"PFS: Time in months from randomization to first documentation of objective disease progression as determined by independent radiology review or to death due to any cause, whichever occurred first. PFS was calculated as (first event date minus the date of randomization plus 1) divided by 30.4. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria version 1.1 (RECIST v1.1), as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG000","title":"Crizotinib"},{"description":"Pemetrexed 500 mg/m\\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) included all participants who were randomized to study treatment.","reportingStatus":"POSTED","timeFrame":"Randomization until progressive disease (PD) or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)","title":"Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}